SPA-1 Activators
SPA-1 activators belong to a specialized chemical class known for their unique ability to modulate cellular processes by targeting a specific protein called SPA-1 (Ser/Pro-rich Area splicing factor 1). SPA-1, also known as SF1 (Splicing Factor 1), is a crucial protein involved in pre-mRNA splicing, an essential step in gene expression regulation. These activators are meticulously designed compounds, primarily researched for their potential to influence splicing events within the cell.
At the heart of SPA-1 activators lies their chemical structure, which is often characterized by a scaffold optimized to interact with SPA-1's binding sites. These molecules possess a distinct three-dimensional arrangement of atoms, enabling them to form specific non-covalent interactions with the protein. These interactions can either enhance or inhibit SPA-1's activity, depending on the specific chemical properties of the activator. Some SPA-1 activators act as agonists, promoting the functional activity of SPA-1, while others function as antagonists, inhibiting its actions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | $720.00 | ||
Tipifarnib inhibits farnesylation of Ras proteins, potentially leading to decreased Ras activity. This decrease in Ras signaling could trigger compensatory responses that indirectly increase the expression or activation of SPA-1 as a means to regulate signaling pathways. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib blocks MEK, a downstream component of Ras signaling. Disruption of the Ras-MEK pathway might induce cellular responses that involve increased SPA-1 expression or activation as part of a feedback mechanism to augment signaling pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets Raf kinases, integral components of the Ras pathway. Alterations in Ras signaling due to Sorafenib may lead to compensatory changes in other signaling elements, potentially including an increase in SPA-1 expression or activation. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
Erlotinib inhibits EGFR, a factor that can influence Ras signaling. Changes in EGFR and Ras signaling due to erlotinib may indirectly affect SPA-1 by potentially increasing its expression or activation through downstream signaling events | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin blocks PI3K, which can interact with Ras pathways. Changes in PI3K and Ras signaling may lead to regulatory responses that include the increased expression or activation of SPA-1. | ||||||